These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 23994365)
1. Reducing mechanical activation-induced amorphisation of salbutamol sulphate by co-processing with selected carboxylic acids. Curtin V; Amharar Y; Gallagher KH; Corcoran S; Tajber L; Corrigan OI; Healy AM Int J Pharm; 2013 Nov; 456(2):508-16. PubMed ID: 23994365 [TBL] [Abstract][Full Text] [Related]
2. Investigation of the capacity of low glass transition temperature excipients to minimize amorphization of sulfadimidine on comilling. Curtin V; Amharar Y; Hu Y; Erxleben A; McArdle P; Caron V; Tajber L; Corrigan OI; Healy AM Mol Pharm; 2013 Jan; 10(1):386-96. PubMed ID: 23186332 [TBL] [Abstract][Full Text] [Related]
3. Mitigating unwanted amorphisation: A screening method for the selection of suitable excipients. Amharar Y; Curtin V; Gallagher KH; O'Siochru E; O'Connell P; Healy AM Eur J Pharm Sci; 2016 Jan; 81():181-8. PubMed ID: 26493586 [TBL] [Abstract][Full Text] [Related]
4. An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approach. Petzoldt C; Bley O; Byard SJ; Andert D; Baumgartner B; Nagel N; Tappertzhofen C; Feth MP Eur J Pharm Biopharm; 2014 Apr; 86(3):337-50. PubMed ID: 24075979 [TBL] [Abstract][Full Text] [Related]
5. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone. Caron V; Tajber L; Corrigan OI; Healy AM Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367 [TBL] [Abstract][Full Text] [Related]
6. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement. Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574 [TBL] [Abstract][Full Text] [Related]
7. Influence of polymer content on stabilizing milled amorphous salbutamol sulphate. Balani PN; Wong SY; Ng WK; Widjaja E; Tan RB; Chan SY Int J Pharm; 2010 May; 391(1-2):125-36. PubMed ID: 20211717 [TBL] [Abstract][Full Text] [Related]
8. Influence of excipients in comilling on mitigating milling-induced amorphization or structural disorder of crystalline pharmaceutical actives. Balani PN; Ng WK; Tan RB; Chan SY J Pharm Sci; 2010 May; 99(5):2462-74. PubMed ID: 19902526 [TBL] [Abstract][Full Text] [Related]
9. Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation. Amharar Y; Curtin V; Gallagher KH; Healy AM Int J Pharm; 2014 Sep; 472(1-2):241-7. PubMed ID: 24968139 [TBL] [Abstract][Full Text] [Related]
10. In situ co-amorphisation of arginine with indomethacin or furosemide during immersion in an acidic medium - A proof of concept study. Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS Eur J Pharm Biopharm; 2018 Dec; 133():151-160. PubMed ID: 30339888 [TBL] [Abstract][Full Text] [Related]
11. In situ amorphisation of indomethacin with Eudragit® E during dissolution. Priemel PA; Laitinen R; Grohganz H; Rades T; Strachan CJ Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1259-65. PubMed ID: 24056054 [TBL] [Abstract][Full Text] [Related]
13. X-ray powder diffractometry in combination with principal component analysis--a tool for monitoring solid state changes. Kogermann K; Veski P; Rantanen J; Naelapää K Eur J Pharm Sci; 2011 Jul; 43(4):278-89. PubMed ID: 21575718 [TBL] [Abstract][Full Text] [Related]
14. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation. Chieng N; Aaltonen J; Saville D; Rades T Eur J Pharm Biopharm; 2009 Jan; 71(1):47-54. PubMed ID: 18644443 [TBL] [Abstract][Full Text] [Related]
15. Measurement of low amounts of amorphous content in hydrophobic active pharmaceutical ingredients with dynamic organic vapor sorption. Müller T; Schiewe J; Smal R; Weiler C; Wolkenhauer M; Steckel H Eur J Pharm Biopharm; 2015 May; 92():102-11. PubMed ID: 25779351 [TBL] [Abstract][Full Text] [Related]
16. The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers. James J; Crean B; Davies M; Toon R; Jinks P; Roberts CJ Int J Pharm; 2008 Sep; 361(1-2):209-21. PubMed ID: 18577435 [TBL] [Abstract][Full Text] [Related]
17. Influence of small amorphous amounts in hydrophilic and hydrophobic APIs on storage stability of dry powder inhalation products. Müller T; Krehl R; Schiewe J; Weiler C; Steckel H Eur J Pharm Biopharm; 2015 May; 92():130-8. PubMed ID: 25769680 [TBL] [Abstract][Full Text] [Related]
18. Following mechanical activation of salbutamol sulphate during ball-milling with isothermal calorimetry. Gaisford S; Dennison M; Tawfik M; Jones MD Int J Pharm; 2010 Jun; 393(1-2):74-8. PubMed ID: 20385222 [TBL] [Abstract][Full Text] [Related]
19. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. Corrigan DO; Corrigan OI; Healy AM Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654 [TBL] [Abstract][Full Text] [Related]
20. Milling induced amorphisation and recrystallization of α-lactose monohydrate. Badal Tejedor M; Pazesh S; Nordgren N; Schuleit M; Rutland MW; Alderborn G; Millqvist-Fureby A Int J Pharm; 2018 Feb; 537(1-2):140-147. PubMed ID: 29262302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]